Please login to the form below

Not currently logged in
Email:
Password:

Array appoints Victor Sandor chief medical officer

He joins from Incyte and will replace Michael Needle

Array Biopharma has named Victor Sandor as its new chief medical officer, handing him responsibility for leading clinical, medical and regulatory strategy and operations across its Array portfolio.

This includes the Colorado, US-based company's binimetinic, a MEK inhibitor in phase III trials for ovarian cancer and melanoma, and filanesib, a KSP inhibitor for multiple myeloma.

Sandor said: “I am pleased to join the Array team at such an exciting time in the company's evolution. In addition to the impressive portfolio of clinical stage assets in development by Array's partners, I look forward to focusing on the development of binimetinib and filanesib, which each target patient populations with significant unmet medical need.”

He brings more than a decade of experience in the pharma and biotech industries to the role, and most recently served as senior VP for global clinical development at Incyte Corporation.

Prior to this he has held VP and CMO for oncology positions at Biogen Idec and also worked on oncology product development at AstraZeneca where he played a role in the registration of Arimidex for adjuvant use.

Ron Squarer, CEO at Array Biopharma, said: “Dr Sandor's leadership, experience and vision will strengthen our clinical development efforts as we advance our late stage, wholly-owned assets towards commercialisation.

“With the possible near-term return of binimetinib to Array, his expertise will have significant unmet medical need.”

16th September 2014

From: Research, Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics